AstraZeneca has discontinued ... The CAPItello-290 study was investigating the drug in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast ...

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

AstraZeneca and Daiichi Sankyo have revealed that their new drug has shown a ‘meaningful improvement’ in survivability rates in patients suffering from an aggressive form of breast cancer.

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

AstraZeneca ... cancer charities. The medicine has been found to double the life expectancy for terminal breast cancer patients. However, Nice ruled that Enhertu did not offer value for money. The ...

AstraZeneca (NASDAQ ... improvement as a first line treatment of metastatic breast cancer, compared to standard care. Enhertu, an antibody drug conjugate, is being jointly developed and ...

AstraZeneca has ... was investigating the drug in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC).